What are the recommended colchicine doses for acute gout flare, gout prophylaxis, familial Mediterranean fever, and acute pericarditis, and how should they be adjusted for renal or hepatic impairment?

Colchicine Dosing Recommendations

For acute gout flares, use low-dose colchicine: 1.2 mg immediately followed by 0.6 mg one hour later, then stop—this regimen is equally effective as high-dose protocols but with significantly fewer gastrointestinal side effects. 1

Acute Gout Flare Treatment

The FDA-approved dosing for acute gout is 1.2 mg (two 0.6 mg tablets) initially, followed by 0.6 mg one hour later 2. This low-dose regimen provides equivalent pain relief to older high-dose protocols (1.2 mg followed by 0.6 mg hourly for 6 hours) while dramatically reducing diarrhea and other GI toxicity 1. Treatment should be initiated within 36 hours of symptom onset for optimal efficacy 3.

Critical caveat: If the patient is already taking prophylactic colchicine, do not use colchicine for the acute flare—choose corticosteroids or NSAIDs instead 3, 2.

Gout Flare Prophylaxis

Standard dose: 0.6 mg once or twice daily (or 0.5 mg once or twice daily outside the US) 3. This prophylaxis should be initiated with or just prior to starting urate-lowering therapy and continued for:

• At least 6 months, OR
• 3 months after achieving target serum urate (if no tophi present), OR
• 6 months after achieving target serum urate (if tophi detected) 3

The 2020 ACR guideline supports colchicine as a first-line prophylactic agent alongside NSAIDs and low-dose corticosteroids 4.

Familial Mediterranean Fever (FMF)

Adults: Start 1.0-1.5 mg daily, maximum 3 mg daily
Children:

• <5 years: ≤0.5 mg/day (≤0.6 mg if using 0.6 mg tablets)
• 5-10 years: 0.5-1.0 mg/day (up to 1.2 mg if using 0.6 mg tablets)

• 10 years: 1.0-1.5 mg/day (up to 1.8 mg if using 0.6 mg tablets)

• Maximum for children: 2 mg daily 5, 6

Doses should be increased gradually (no more frequently than weekly) to control attacks and normalize inflammatory markers 6. Monitor response every 3-6 months initially, then every 6 months once stable 5.

Acute Pericarditis

While colchicine is used for pericarditis, the evidence provided does not specify exact dosing for this indication 7. General medical knowledge suggests 0.5-0.6 mg twice daily for 3 months for acute pericarditis, but this requires confirmation from pericarditis-specific guidelines.

---

Renal Impairment Adjustments

Acute Gout Flare Treatment:

• Mild-moderate impairment (CrCl 30-80 mL/min): No dose adjustment needed, but monitor closely 2
• Severe impairment (CrCl <30 mL/min): Use standard dose (1.2 mg then 0.6 mg), but do not repeat course more than once every 2 weeks 2
• Dialysis patients: Single dose of 0.6 mg only; do not repeat more than once every 2 weeks 2

Gout Prophylaxis:

• Mild-moderate impairment (CrCl 30-80 mL/min): No adjustment needed, monitor closely 2
• Severe impairment (CrCl <30 mL/min): Start 0.3 mg daily; increase cautiously with close monitoring 2
• Dialysis patients: 0.3 mg twice weekly 2

FMF:

• Mild-moderate impairment: Monitor closely; dose reduction may be necessary 2
• Severe impairment/dialysis: Start 0.3 mg daily; increase only with careful monitoring 2

Important: Pharmacokinetic modeling demonstrates that standard 0.6 mg daily dosing in moderate-to-severe renal impairment results in supratherapeutic levels 10-36% of the time, while 0.3 mg every-other-day results in subtherapeutic levels 20-70% of the time 8. The optimal approach is 0.48-0.5 mg daily for moderate impairment and 0.3 mg daily for severe impairment 8.

---

Hepatic Impairment Adjustments

Acute Gout Flare Treatment:

• Mild-moderate impairment: No adjustment needed, monitor closely 2
• Severe impairment: Use standard dose, but do not repeat course more than once every 2 weeks 2

Gout Prophylaxis:

• Mild-moderate impairment: No adjustment needed, monitor closely 2
• Severe impairment: Consider dose reduction 2

FMF:

• Mild-moderate impairment: Monitor closely 2
• Severe impairment: Dose reduction recommended; colchicine half-life may be up to 7-fold longer in cirrhosis 5

---

Drug Interactions Requiring Dose Reduction

Colchicine is contraindicated in patients with renal or hepatic impairment who are taking potent CYP3A4 or P-glycoprotein inhibitors 1, 2.

For patients with normal renal and hepatic function taking strong CYP3A4 inhibitors (macrolides, azole antifungals, protease inhibitors, verapamil, diltiazem):

Acute Gout Flare:

• Reduce to 0.6 mg × 1 dose, followed by 0.3 mg 1 hour later
• Do not repeat for at least 3 days 2

Gout Prophylaxis:

• If taking 0.6 mg twice daily → reduce to 0.3 mg once daily
• If taking 0.6 mg once daily → reduce to 0.3 mg every other day 2

Do not treat acute flares with colchicine in patients already on prophylactic colchicine plus CYP3A4 inhibitors 2.

---

Toxicity Warning

Maximum doses: 3 mg/day in adults, 2 mg/day in children 5. Exceeding these doses, combined with renal/hepatic impairment, or drug interactions can cause life-threatening toxicity with a triphasic presentation:

1. Stage 1 (0-24h): Cholera-like GI symptoms, dehydration, shock
2. Stage 2 (24-72h): Multiorgan failure, bone marrow suppression, ARDS, arrhythmias, DIC, coma
3. Stage 3 (weeks): Recovery with rebound leukocytosis, alopecia 5

No antidote exists—management is purely supportive 5. First sign of toxicity is diarrhea; reduce dose immediately 3.